The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / Sept / Preparing for CPHI 2025 in Frankfurt
Industry News Sponsored

Preparing for CPHI 2025 in Frankfurt

Our interview with Tara Dougal offers a snapshot of what to expect at the event.

09/23/2025 0 min read

Sponsored By

Informa Markets

Share

Running from October 28 to 30 at Messe Frankfurt, Germany, CPHI Frankfurt is expected to draw more than 63,000 attendees. The event brings together professionals from across the drug development and manufacturing ecosystem, and will feature six content theaters, more than 2,000 exhibitors, and a packed program focusing on networking and innovation. New zones have also been introduced to spotlight topics such as digital health technologies, AI-powered drug development, and sustainable pharma manufacturing.

Learn more about the event in this interview with Tara Dougal, Event Director – Pharma at Informa Markets.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Novartis and BMS Pause Autoimmune CAR T Trials Over Safety Concerns
Cell & Gene Industry News
Novartis and BMS Pause Autoimmune CAR T Trials Over Safety Concerns

September 16, 2026

2 min read

Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
Industry News Research News Cell & Gene
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

September 16, 2026

2 min read

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
Cell & Gene Industry News Research News
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

August 31, 2026

4 min read

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

Phase III Success Marks Milestone for Personalized Cancer Vaccines
Biopharma Industry News Development & Clinical
Phase III Success Marks Milestone for Personalized Cancer Vaccines

August 26, 2026

7 min read

Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: